RNA Outsourcing Videos

1. The Current State of CDMO Platforms For gRNA Production 4/29/2026

   Max De Long, April Sena, and Venkat Krishnamurthy share their perspectives on the current “health” of CDMO SPOS and enzymatic ligation platforms, while also highlighting the “red flags” to look out for when taking stock of a CDMOs capabilities. 

2. LNP And Liposomal Center Of Excellence 3/10/2026

   A connected development pathway supports smoother scale-up and greater consistency for LNP-based therapeutics. Explore how integrated expertise across key stages helps teams accelerate progress.

3. Customized mRNA Processing For Improved Therapy Development And Manufacturing 2/13/2025

   Optimize mRNA development by learning key strategies for process refinement, critical component identification, and in-process analytics to enhance therapeutic production.

4. Intelligent mRNA Manufacturing Through Process Analytical Technologies 3/10/2025

   Learn how predictive models can monitor key CQAs, such as RNA concentration and nucleoside triphosphate consumption, and explore RBP and MIT’s vision for revolutionizing biomanufacturing.

5. From Cell Bank To Clinic Faster: GMP Manufacturing & Characterization 7/28/2026

   Accelerate your path to the clinic with an integrated, risk-based cell banking strategy that delivers speed, quality, and regulatory confidence at every stage.

6. Our Experience Creates Reliable Results 6/27/2024

   Hear from inSeption Group clients as they share their experiences, recount their journeys and highlight the exceptional service and support they received.

7. Enhancing Gene Editing Outcomes And Safety for Clinical Translation 5/6/2026

   Learn how streamlined vector backbones can improve efficiency, consistency, and expression durability when reliability matters most.

8. ICH E6(R3): Practical Steps For Implementation 12/14/2023

   Watch this presentation to equip stakeholders with actionable strategies and a comprehensive understanding of the evolving clinical trial management landscape in the context of ICH guidelines.

9. From Lipids To Launch: End-To-End Therapy Development 8/20/2026

   Explore integrated capabilities spanning lipid manufacturing, nanoparticle formulation, and more with support designed to move complex therapies from preclinical development through commercialization.

10. mRNA's Impact On Cost And Capacity To Surge Biopharma Production 5/22/2023

    TFF Pharmaceuticals’ Kayla Hannon and University of Sheffield’s Dr. Zoltán Kis discuss the cost and capacity implications of therapeutic demand surges in this Surge Manufacturing for Biopharma Resilience segment.